amendment, examined the claims and rejected them based on prior art. Thus, it is believed that the restriction requirement has been withdrawn and the election has become moot.

The Rejection Under 35 U.S.C. § 102(b)

The Examiner has rejected Claims 23-31 under 35 U.S.C. § 102(b) as being anticipated by the mere recitation of a condensed phosphate or polyphosphate salt in low pH beverages in any of the various patents cited by the Examiner on Form PTO-892. The Examiner states that the Dental Erosion Benefit is inherent in anyone of the 10 references relied upon. The Applicant respectfully traverses this rejection and asserts that any rejection of Claims 23-31 based on inherency and in view of any of the U.S. Patents cited on Examiner's Form PTO-892, is untenable and should be withdrawn. These method claims are not anticipated based on inherency because each and every element of the claims is not disclosed in any of the cited patents, either expressly or inherently. See Verdegaal Bros. v. Union Oil Co., 2 USPQ2d 1051, 1053 (Fed. Cir. 1987).

Indeed, a key limitation of the method Claims 23-31 is that they are "methods for treating dental erosion". There is no mention in any of the patents cited by the Examiner that the juice compositions be used in any dental treatment methods whatsoever. As such, the present methods are not taught, suggested, or even inherently present in any of the cited patents. Moreover, there is no extrinsic evidence, which may be used to show that the missing descriptive matter is necessarily, or even possibly, present in the cited patents. See Continental Can Co. v. Monsanto Co., 20 USPQ2d 1746, 1749 (Fed. Cir. 1991). Accordingly, the cited case law of Atlas Powder and Ex parte Novitski is irrelevant in view of the presently pending claims, as there is no inherent presence of the claimed subject matter set forth in the patent references presented by the Examiner. Any rejection of Claims 23-31 based on inherency is therefore misplaced and should be withdrawn.

Apparent rejection of the "KIT" claims based on In re Haller

The Examiner appears to reject Claims 11 – 15, 17 – 20, and 22 in view of any of the various U.S. patents cited by the Examiner on Form PTO-892, based on *In re Haller*, 73 USPQ 403 (CCPA 1947). The Examiner has cited *Haller* for the premise that "novelty cannot be predicated on printed instructions." The Applicant respectfully traverses this rejection and the Examiner's reliance on *Haller*. Indeed, in the more contemporary cases *In re Miller*, 164 USPQ 46 (CCPA 1969) and *In re Gulack*, 217 USPQ 401 (Fed. Cir. 1983), which were both subsequent to *Haller*, articles comprising previously known compositions, in association with information which was functionally related to such composition, were held novel and non-obvious over the known compositions. For example, in *Miller*, which related to printed information on a measuring device, the Court stated:

[The Examiner's] characterization of printed matter as "unpatentable" is beside the point; no attempt is here being made to patent printed matter as such. The fact that printed matter by itself is not patentable subject matter, because non-statutory, is no reason for ignoring it when the claim is directed to a combination. Here there is a new and unobvious functional relationship between a measuring receptacle, volumetric indicia thereon . . . and a legend indicating the ratio, and in our judgment the appealed claims properly define this relationship.

See Miller, at third paragraph from conclusion of opinion (emphasis added).

Indeed, the PTO supports *Miller*, and *only* directs claim rejections in view of 35 U.S.C. 101 and *Miller* when a mere arrangement of printed matter is claimed. <u>See MPEP 706.03(a)</u>.

The Federal Circuit affirmed *Miller* in *Gulack*, even while recognizing that the "sole difference" between the claimed article and the prior art composition was the printed material. In *Gulack*, the Federal Circuit stated:

A functional relationship of the precise type found by the CCPA in *Miller* – to size or to type of substrate, or conveying information about [the] substrate – is not required. What is required is the existence of differences between the appealed claims and the prior art sufficient to establish patentability.

See Gulack, Section II, B.

Taken in the context of the present invention, Claims 11 - 15, 17 - 20, and 22 are indeed patentable over the cited U.S. patents. The information referred to in independent Claim 11, *i.e.*, information that use of the beverage composition provides treatment against dental erosion, is clearly functionally related to the beverage composition itself. It is representative of the present discovery that the polyphosphate compounds recited in the claims are surprisingly effective against dental erosion. Moreover, the kits of Claims 11 - 15, 17 - 20, and 22 are directive, such that a consumer will understand the present discovery and have the ability to capitalize on such discovery. Thus, the utility of the present compositions is furthered because the consumer will understand the benefits, and be encouraged to utilize, the beverage composition based on this surprising and previously unknown use.

Applicant asserts that there are indeed differences between the cited art and the presently claimed kits, rendering the kits novel and unanticipated under 35 U.S.C. § 102. Like Gulack and Miller, the differences are largely related to the information. Moreover, this information is functionally related to the beverage of the recited kits (as highlighted in Gulack, yet "not required" under Miller). This information is a reflection of the present discovery that the recited compositions are surprisingly useful against dental erosion; Applicants have a legal right to protect this novel discovery. Applicant finds nothing in Gulack and Miller that should preclude Applicant from this

legal right, and the Examiner has not provided guidance with regard to any rationale to the contrary. Applicant therefore strongly asserts that the Examiner should withdraw the rejection based on *In re Haller* and allow the claims as pending.

Notwithstanding, the Examiner makes the blanket statement that it is the PTO's position to distinguish *Miller/Gulack* in favor of *Haller*, based on the facts of the present application. In doing so, the Examiner fails to provide Applicant with any rationale, explanation, or guidance for this "official" position. The Examiner fails to guide Applicant as to why *Haller* should be followed based on the present circumstances, and why *Miller/Gulack* should not be followed. Accordingly, if the Examiner persists in the present rejection, as based on an application of *Haller*, Applicant respectfully requests that the Examiner explain a specific and clear rationale of the basis of the rejection and choice of law.

The Rejections Under 35 U.S.C. § 103(a)

The Examiner has rejected Claims 11 – 15, and 17 – 20 and 22 under 35 U.S.C. § 103(a) as allegedly being non-obvious over the cited references. In particular, the Examiner has combined any of the various patents cited by the Examiner on Form PTO-892 in view of each of Shibata *et al.*, "Antibacterial Action of Condensed Phosphates on the Bacterium *Streptococcus Mutans* and Experimental Caries in the Hamster," Archives of Oral Biology, Vol. 27, pp. 809 – 816 (1982) (herein referred to as Shibata *et al.*) or McGaughey *et al.*, "Effects of Polyphosphates on the Solubility and Mineralization of HA: Relevance to a Rationale for Anticaries Activity," *Journal of Dentistry Research*, Vol. 56, No. 6, pp. 579 – 587 (June 1977) (herein referred to as McGaughey *et al.*) and each of previously cited Muhler and McDonald *et al.*

To establish obviousness, three basic criteria must be met. First, there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference. Second, there must be a reasonable expectation of success in making the modification. Finally, the prior art reference must teach or suggest all the claimed limitations and the reasonable expectation of success must both be found in the prior art and not based on Applicants' disclosure. See In re Vaeck, 20 USPQ2d 1438 (Fed. Cir. 1991).

For the reasons stated above and as supported by established law, it would have been non-obvious to one of ordinary skill to use the recited polyphosphate compositions to treat dental erosion and to therefore provide kits which disseminate information regarding such treatment. Applicant asserts that, while the cited U.S. patents collectively disclose the polyphosphate compound utilized in the present claims, the patents fail to disclose, teach, or even suggest any use against dental erosion. Moreover, these references fail to suggest that the presently recited polyphosphate

compounds would be useful as a substitute for the monosodium dihydrogen phosphate ("MDP", NaH₂PO₄) of Muhler and McDonald *et al.* for the purpose of treating dental erosion. Indeed, Applicant has amended independent Claim 11 to require that the claimed beverage composition comprises less than about 0.025% of orthophosphate (*i.e.*, MDP), by weight of the composition. This is reflective of Applicant's unique and surprising discovery that the recited linear polyphosphates have effective utility against dental erosion.

Shibata et al. and McGaughey et al. recite the use of condensed phosphates at elevated pH in the diet for treatment of caries, not dental erosion. However, as claimed, the present kits comprise beverage compositions having a pH of less than about 5. It is well-known in the art that acidic compositions are actually considered to exacerbate dental erosion (which occurs by direct action of acid on the enamel surface). See specification at page 1 and Lussi et al., "Prediction of the Erosive Potential of Some Beverages", Caries Research, Vol. 29, pp. 349 – 354 (1995), which examined the erosive potential of many beverage compositions, all having a pH of less than 5.

Taken together, therefore, the Examiner's cited combination of references fails to teach or even suggest the presently claimed kits. Firstly, and following the dictates of the law regarding non-obviousness, there would have been no motivation or suggestion in the references to made any modification which would arrive at the present kits. The present kits claim beverage compositions having acidic pH and comprising the defined linear polyphosphates and explicitly less than about 0.025% orthophosphate, all together with information that these acidic beverage compositions provide treatment against dental erosion. This is unexpected in light of the combined references, and in view of the literature generally, which would preclude any motivation to modify. Secondly, but similarly, there would have been no reasonable expectation of success for the same foregoing reasons. Finally, the combination of references fails to teach or suggest all of the claimed limitations, particularly with regard to the definition of the linear polyphosphate compound, the acidity of the beverage composition, and the surprising information associated therewith. Respectfully, the Examiner has therefore failed to establish any obviousness of the presently claimed kits.

For all of the foregoing reasons, Applicant therefore asserts that the claimed kits are indeed novel and non-obvious over the cited references and in view of the consistent controlling authority. Applicant therefore requests that the Examiner withdraw the rejections and promptly allow the claims as amended herein.

CONCLUSION

For all of the above reasons, it is respectfully requested that the Examiner withdraw the rejections under 35 U.S.C. §§ 102(b) and 103(a) and allow Claims 11 - 15, 17 - 20, and 22-31 as

pending herein. If the Examiner believes that personal contact would be advantageous to the disposition of this case, he is respectfully requested to contact the undersigned at his earliest convenience.

Respectfully submitted,

S. Robert Chuey

Attorney for Applicant Registration No. 39,140

Tel: 513-634-0102

Dated: November 15, 2002

Customer No. 27752